A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients by Engelhardt, M. (Monika) et al.
910 haematologica | 2017; 102(5)
Received: December 19, 2016. 
Accepted: January 25, 2017.
Pre-published: February 2, 2017.
©2017 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright.
All rights are reserved to the Ferrata Storti Foundation. Use of
published material is allowed under the following terms and
conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode. 
Copies of published material are allowed for personal or inter-
nal use. Sharing published material for non-commercial pur-
poses is subject to the following conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode,
sect. 3. Reproducing and sharing published material for com-
mercial purposes is not allowed without permission in writing
from the publisher.
Correspondence: 
monika.engelhardt@uniklinik-freiburg.de
Ferrata Storti
Foundation
EUROPEAN
HEMATOLOGY
ASSOCIATION
Haematologica 2017
Volume 102(5):910-921
ARTICLE Plasma Cell Disorders
doi:10.3324/haematol.2016.162693
Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/102/5/910
With growing numbers of elderly multiple myeloma patients, reli-able tools to assess their vulnerability are required. The objec-tive of the analysis herein was to develop and validate an easy
to use myeloma risk score (revised Myeloma Comorbidity Index) that
allows for risk prediction of overall survival and progression-free survival
differences in a large patient cohort. We conducted a comprehensive
comorbidity, frailty and disability evaluation in 801 consecutive myeloma
patients, including comorbidity risks obtained at diagnosis. The cohort
was examined within a training and validation set. Multivariate analysis
determined renal, lung and Karnofsky Performance Status impairment,
frailty and age as significant risks for overall survival. These were com-
bined in a weighted revised Myeloma Comorbidity Index, allowing for
the identification of fit (revised Myeloma Comorbidity Index ≤3 [n=247,
30.8%]), intermediate-fit (revised Myeloma Comorbidity Index 4-6
[n=446, 55.7%]) and frail patients (revised Myeloma Comorbidity Index
>6 [n=108, 13.5%]): these subgroups, confirmed via validation analysis,
showed median overall survival rates of 10.1, 4.4 and 1.2 years, respec-
tively. The revised Myeloma Comorbidity Index was compared to other
commonly used comorbidity indices (Charlson Comorbidity Index,
Hematopoietic Cell Transplantation-Specific Comorbidity Index, Kaplan-
Feinstein Index): if each were divided in risk groups based on 25% and
75% quartiles, highest hazard ratios, best prediction and Brier scores were
achieved with the revised Myeloma Comorbidity Index. The advantages
of the revised Myeloma Comorbidity Index include its accurate assess-
ment of patients' physical conditions and simple clinical applicability. We
propose the revised Myeloma Comorbidity Index to be tested with the
"reference" International Myeloma Working Group frailty score in multi-
center analyses and future clinical trials. The study was registered at the
German Clinical Trials Register (DRKS-00003868).
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ABSTRACT
Introduction 
Over the past decade, overall survival (OS) has
improved significantly in patients with multiple myeloma
(MM). This is driven by better biological insights in the
disease, implementation of more sensitive tests and tech-
nologies leading to earlier diagnosis, access to better com-
bination therapies and increased access to supportive care
measures.1-3 However, MM typically affects elderly
patients, who face the challenge that treatment endurance
is poorer and prognosis more unfavorable.4,5 Moreover, the
simultaneous presence of additional diseases may compli-
cate antimyeloma treatment.1,3 In general, comorbidities
have been shown to influence cancer patients’ general
health status, limit their physical condition and OS.6-11
Therefore, with a growing number of elderly patients, reli-
able tools to assess patients' vulnerability as expressed in
chronic conditions and limitations in daily activity are
required to guide therapeutic decisions.4,12-15
Historically, treatment decisions in symptomatic MM
patients have been largely age-based. Today, disease biol-
ogy and fitness, including patients' Karnofsky
Performance Status (KPS), are considered when assessing
therapeutic options.3,14 However, the KPS is often overesti-
mated and does not reflect the entire functional status.10
Therefore, advances in more precise ways of defining fit-
ness are warranted. Moreover, since elderly MM patients
are often excluded from clinical trials due to strict inclu-
sion criteria,16 these trial results are not necessarily trans-
ferable to elderly patients. In this context, the
International Myeloma Working Group (IMWG),
European Myeloma Network (EMN) and others (e.g., IFM,
HOVON, DSMM, GMMG) recommended that age, phys-
ical condition and comorbidities are included in therapy
decisions.1,8,10,12,14 Since cytogenetic aberrations are addi-
tional prognostic factors in MM,17-20 it may also be impor-
tant to include cytogenetics in MM-specific risk scores.
Risk scores for MM have indeed included disease-related
risks (the International Staging System (ISS), lactate dehy-
drogenase (LDH), cytogenetics), combined comorbidities
with cytogenetics or multiple comorbidity screening tests
(IMWG frailty score).12,17-19 Our prior test8 and independent
validation analyses9,10 defined impaired renal function,
lung function or KPS as relevant risks via thoroughly
assessed univariate and multivariate analyses. These vari-
ables were combined in an additive Initial Myeloma
Comorbidity Index (I-MCI),8-10 which enabled the clear
definition of risk groups with substantially different pro-
gression-free survival (PFS) and OS. Furthermore, it was
found to add valuable information to the ISS.10
In order to refine and weight our I-MCI, we tested and
validated a 'revised MCI' (R-MCI) based on a large cohort
of 801 MM patients. Additionally, we compared the R-
MCI to other internationally used Comorbidity Indices
(CIs), namely Charlson CI (CCI), Hematopoietic Cell
Transplantation-specific CI (HCT-CI) and Kaplan-
Feinstein Index (KFI). Frailty scores are already used clini-
cally for various cancers, but a comprehensive comorbidi-
ty, frailty and disability evaluation is time-consuming and
less applicable outside centers with oncogeriatric teams,21
which was the reason why we aimed to establish a con-
cise, time-saving R-MCI.
Since the comparison of the Initial-/R-MCI (I-/R-MCI)
with the IMWG frailty score was already meticulously
performed by us,22 it was not the focus of this analysis,
rather, the aim was to define a concise, weighted, both
tested and validated MM-specific risk score in a large
cohort which could be subsequently used for the measure-
ment of frailty in multicenter analyses and future clinical
trials. 
Methods
Patient population and study design
This prospective assessment was based on the analysis of 801
consecutive MM patients at the time of initial diagnosis and first
presentation at our center between 1997 and 2012. The study was
registered at the German Clinical Trials Register (DRKS-
00003868). The primary objective was to optimize the I-MCI8-10
within a weighted R-MCI in a large myeloma cohort. Secondary
objectives included the impact of the R-MCI as compared to the I-
MCI, CCI, HCT-CI and KFI (Online Supplementary Table S1), and
their value for PFS and OS. The analysis was carried out according
to the guidelines of the Declaration of Helsinki principles and good
clinical practice. All patients gave their written informed consent
for institutional-initiated research studies and analyses of clinical
outcome studies conforming to the institutional review board
guidelines. 
Assessment
The I-MCI consists of an additive scoring system, namely
renal, lung and/or KPS impairment.8-10 In order to weight this in
an even larger cohort, 13 comorbidities were assessed in 801
patients: these were graded and rated according to Common
Terminology Criteria for Adverse Events (CTCAE) 4.03, which
included: renal, lung and KPS impairment, cardiac, liver or gas-
trointestinal disease, disability, frailty, infection, thromboembol-
ic events, peripheral neuropathy, pain and secondary malignan-
cies (Table 1). In addition, age, cytogenetics via fluorescence in
situ hybridization (FISH after CD138 selection), renal function
(via estimated glomerular filtration rate [eGFRMDRD]) and lung dis-
ease, including lung function tests, were determined as
described.8-11,22-25 We performed interphase FISH on CD138+ plas-
ma cells, which were analyzed using DNA probes specific for
the following chromosomal aberrations: t(11;14)(q13;q32),
t(4;14)(p16;q32), t(14;16)(q32;q23) and t(14;20)(q32;q12 (Abbott
Laboratories, IL, USA), XL 5q31/5p12, XCE 9, 11, 15, gain(1q21),
del(1p32), del(13q14), del(17p13) and c-myc rearrangements
(MetaSystems, Altlussheim, Germany). The score of Wuilleme et
al.26 was used to assess ploidy by using gains of at least two of
the chromosomes. For each probe a minimum of 100 nuclei
were scored.  European Myeloma Network (EMN) cutoff values
were applied for the detection of aberrations.27 Unfavorable
cytogenetics were defined as del(17p13), del(13q14), t(4;14),
t(14;16), t(14;20), hypodiploidy, c-myc and chromosome 1 aber-
rations.1,8,10,22,24,27-31 The KPS was defined as normal (100%), mildly
(90%), moderately (80%) or more substantially impaired
(≤70%). Frailty and disability were assessed in order to get a
more precise determination of patients’ physical condition. The
Fried definition for frailty was used, which takes into account
the added presence of weakness, poor endurance, low physical
activity, slow gait speed and shrinking, with ≤2 factors defining
frailty as moderate and with ≥3 factors determining frailty as
severe.32-34 The assessment was performed by a staff member
trained in oncogeriatrics (A-SD, SMD, AZ, SJM), and was per-
formed identically throughout the study period. Patient charac-
teristics included age, myeloma type, stage, β2-microglobulin
(β2-MG), creatinine, bone marrow (BM) infiltration, cytogenet-
ics and treatment (Table 2).
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Statistical analysis
Data were analyzed using SAS 9.2 (SAS Institute Inc., NC,
USA). OS was calculated from the date of initial diagnosis until the
date of death from any cause, while PFS was calculated from the
date of initial diagnosis until the date of progression, relapse or
death from any cause. When no event of interest occurred, obser-
vations were censored at the time the patient was last seen
alive/without documented event, or at the latest on June 1st, 2015.
OS and PFS rates were estimated using the Kaplan-Meier method,
and compared using the log-rank test.
In order to weight the MCI in a large cohort,8-10 the data set was
randomly split into 2/3 and 1/3, namely a training (n=552) and val-
idation set (n=249). The training set was built by randomly draw-
ing 552 samples. The training set was used to develop the R-MCI,
and the validation set to validate our results. Multivariate Cox pro-
portional hazards regression models with backward variable selec-
tion were applied to the training set to evaluate the prognostic sig-
nificance of the comorbidity factors. Variable selection was based
on complete case analysis. For all other variables, the 552 patients
without any missing data with 294 events (deaths) were used. The
results of the final model with prognostic factors contributing to
the R-MCI were presented as estimated hazard ratios (HRs) with
two-sided 95% confidence interval (CI), corresponding log hazard
ratios and P-values (Table 3). Score weights were determined
based on log hazard ratios, i.e., the regression coefficients of the
prognostic factors, as these reflect the level of association with the
outcome of OS on an additive scale. We assigned a score weight
of 0 if the log hazard ratio was below 0.3, a score weight of 1 if
the log hazard ratio was between 0.31 and 0.7, a score weight of
2 if the log hazard ratio was between 0.71 and 1.07, and a score
weight of 3 if the log hazard ratio was 1.08 or higher, leading to a
maximum of 9 points (Table 3). This rule very closely approxi-
mates the weights as described.35 In order to additionally evaluate
whether the co-variable cytogenetics can increase the predictive
performance of this score (Table 3), a multivariate Cox model
including a preliminary score as a co-variable was compared to a
multivariable Cox model including both the preliminary score and
cytogenetics: the models were based on 353 patients without any
missing data in all co-variables, with or without the inclusion of
cytogenetics (Table 3).17–20 Prediction errors based on the Brier
score36 were used to compare the R-MCI, with and without cyto-
genetics, determining that the R-MCI could be improved with the
inclusion of cytogenetics (Online Supplementary Figure S1). Of note,
our final 9-point weighted R-MCI can be used as a risk tool both
with or without cytogenetics (e.g., if cytogenetics were unavail-
able). Albeit there was no missing data for the prognostic factors
M. Engelhardt et al.
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Table 1. Definition and grading of 13 comorbidities and physical functions in myeloma patients.
Variables Mild Definition and grading Severe References
Moderate
1. Renal function: CTCAE grade 1 CTCAE grade 2 CTCAE grade 3-4 Kleber8–10
eGFR / serum creatinine
2. Lung function: dyspnea upon intense activity, dyspnea upon moderate dyspnea at rest/few steps Kleber8–10
dyspnea or FEV1/FVCa, mildly altered lung function activity,  moderately altered taken/the need for
FEV1, TLC, respiratory lung function or respiratory oxygen/non-invasive
insufficiency insufficiency ventilation or FEV1<50%
3. Karnofsky Performance 90% 80% ≤70% Kleber8–10
Status
4. Cardiac function: CTCAE grade 1 CTCAE grade 2 CTCAE grade 3-4 CTCAE, 4.0
arrhythmias, myocardial 
infarction/CAD, heart failure
5. Hepatic function: CTCAE grade 1 CTCAE grade 2 CTCAE grade 3-4 CTCAE, 4.0
chronic hepatitis, cirrhosis, 
fibrosis, hyperbilirubinemia
6. GI disease: CTCAE grade 1 CTCAE grade 2 CTCAE grade 3 CTCAE, 4.0
nausea, vomiting, diarrhea, ulcer
7. Disability: occasional frequent ≥1x/day Palumbo12
help in personal care 
and household tasks
8. Frailty: 1 factor 2 factors ≥3 factors Rodriguez-Mañas,32
weakness, poor endurance, Xue33
low physical activity, slow gait speed
9. Infection local intervention oral intervention i.v. intervention CTCAE, 4.0
10. Thromboembolic event venous thrombosis thrombosis, medical life-threatening, urgent CTCAE, 4.0
intervention indicated intervention indicated Kristinsson47
11. PNP CTCAE grade 1 CTCAE grade 2 CTCAE grade 3-4 CTCAE, 4.0
12. Pain CTCAE grade 1 CTCAE grade 2 CTCAE grade 3-4 CTCAE, 4.0
13. Secondary malignancy 1. chronological criteria: before, synchronous or after MM Hasskarl28
2. local criteria: local vs. disseminated cancer Engelhardt24
3. etiological criteria: hematological, solid or skin tumors Kleber8–10
aFEV1/FVC: Tiffeneau-Pinelli Index: ratio of the forced expiratory volume in 1 second and the forced vital capacity.  CAD: Coronary Artery Disease; CTCAE: Common Terminology Criteria
for Adverse Events; eGFR: estimated glomerular filtration rate; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; GI: gastrointestinal; PNP: peripheral neuropathy;
TLC: total lung capacity; i.v.: intravenous; I-MCI: Initial Myeloma Comorbidity.
I-MCI
in our dataset, the provision of weighing unfavorable, favorable vs.
"missing/unavailable cytogenetics" within this R-MCI, illustrates
its usefulness for primary or secondary institutions and non-acad-
emic centers.
The R-MCI was also compared to the I-MCI, CCI, HCT-CI and
KFI, evaluating the prognostic role on OS with Cox regression
models (Table 4) in terms of HRs. The predictive ability of differ-
ent scores was assessed using prediction error curves and Brier
scores (Online Supplementary Figure S2):36 the smaller this prediction
error is, the better the curves' prediction rate turns out, with the
'reference' constituting a model without co-variables.
Additionally, the R-MCI was assessed on OS in patients with dif-
ferent antimyeloma treatments and ages. Since the comparison of
the MCI with the IMWG frailty score had already been per-
formed,22 it was not the focus of this analysis, which was rather to
define a weighted, tested and validated MM-specific risk score in
a large myeloma cohort.
Results
Patient characteristics
The analysis included 801 consecutive MM patients.
The median follow up was 6.1 years. The median age was
63 years: 28% of patients were 66-75 years and 13% older
than 75 years, which is very typical for tertiary centers.7-
11,22,24,37,38 Gender distribution and myeloma subtypes corre-
sponded to the data as described.7-11,24 Other characteristics
were likewise representative of large MM centers, e.g.,
typical paraprotein frequencies and mostly advanced
Durie-Salmon and ISS II/III disease stages. The median β2-
MG level was 4.5mg/dL, renal function showed a median
creatinine level of 0.93mg/dL and BM plasma cell infiltra-
tion of 30%. Patients underwent treatment according to
international guidelines, labels and practices as
described.1,10,11,22,24 Autologous stem cell transplantation
Comprehensive appraisal of a weighted myeloma comorbidity index
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Table 2. Patient characteristics.
Entire cohort (n=801) Training set (n=552 / 68.9%) Validation set (n=249 / 31.1%)
n (%) Median (range) n (%) Median (range) n (%) Median (range)
Patient-specific data
Male : female 450 (56.2) : 351 (43.8) 316 (57) : 236 (43) 134 (53.8) : 115 (46.2)
Age (years) 63 (21-93)* 62 (21-93) 63 (32-89)
MM-specific data
Type of myeloma
IgG / IgA 455 (56.8) / 152 (19.0) 309 (56.0) / 105 (19.0) 146 (58.6) / 47 (18.9)
IgM / IgD 6 (0.8) / 2 (0.2) 3 (0.5) / 2 (0.4) 3 (1.2) / 0 (0)
Light-chain MM only 162 (20.2) 117 (21.0) 45 (18.1)
Biclonal (HC) 6 (0.8) 4 (0.7) 2 (0.8)
Non-secretory 18 (2.3) 12 (2.2) 6 (2.4)
κ/l 502 (62.7) / 276 (34.5) 355 (64.1) / 181 (32.9) 147 (59.0) / 95 (38.2)
Biclonal (LC) 5 (0.6) 4 (0.7) 1 (0.4)
Non-secretory 18 (2.3) 12 (2.2) 6 (2.4)
Durie-Salmon
I 204 (25.5) 139 (25.3) 65 (26.1)
II 117 (14.6) 88 (15.8) 29 (11.7)
III 480 (59.9) 325 (58.9) 155 (62.2)
A / B 665 (83.1) / 136 (16.9) 456 (82.6) / 96 (17.4) 209 (83.9) / 40 (16.1)
ISS 759 (94.8)a 517 (93.5) 242 (97.2)
I 225 (28.2) 146 (26.5) 79 (31.7)
II 206 (25.8) 139 (25.3) 67 (26.9)
III 328 (41.0) 232 (42.0) 96 (38.6)
Laboratory parameters
β2-microglobulin (mg/dL) 755 (94.3)e 4.5 (1.1-65.5) 516 (93.5) 4.72 (1.1-65.5) 240 (96.4) 4.20 (1.4-52.6)
Creatinine (mg/dL) 0.93 (0.4-17.9) 0.92 (0.4-17.9) 0.94 (0.5-10.5)
BM infiltration rate (%) 695 (86.8)d 30 (0-100) 487 (88.2) 30 (0-100) 208 (83.5) 30 (0-90)
Cytogenetics
Favorable 316 (39.5) 214 (38.8) 102 (41.0)
Unfavorableb 212 (26.5) 140 (25.4) 72 (28.9)
Missing 273 (34.1) 198 (35.9) 75 (30.1)
Therapy
SCT with novel agents 300 (37.5) 194 (35.1) 106 (42.6)
SCT w/o novel agents 83 (10.4) 62 (11.2) 21 (8.4)
Standard with novel agents 173 (21.6) 118 (21.4) 55 (22.1)
Standard w/o novel agentsc 170 (21.2) 127 (23.1) 43 (17.3)
w/o CTx# 75 (9.4) 51 (9.3) 24 (9.6)
*13% of patients were >75 years, 7% were 76-79 years and 6.3% ≥80 years. aNot evaluated in n=42 patients because of missing data. bUnfavorable cytogenetics defined as del(17p13),
del(13q14), t(4;14), t(14;16), t(14;20), hypodiploidy, c-myc and chromosome 1 aberrations. cNovel agents: e.g., thalidomide, lenalidomide, bortezomib. dNot evaluated in n=106 patients
because of missing data. eNot evaluated in n=46 patients because of missing data. #Radiotherapy and steroids alone. n: number; Ig: immunoglobulin; HC: heavy-chain; MM: multiple myelo-
ma; LC: light-chain; ISS: International Staging System; BM: bone marrow; SCT: stem cell transplantation; w/o CTx: without chemotherapy; κ / l: kappa / lambda.
(ASCT) was recommended for medically fit, symptomatic
patients up to the age of 70 years.22,25 Induction usually
consisted of bortezomib-based regimens, such as VCD
(bortezomib, cyclophosphamide and dexamethasone) or
CTD (cyclophosphamide, thalidomide and dexametha-
sone). Mobilization and conditioning were performed as
described.1,10,11,23,24 Patients ineligible for ASCT received
melphalan, prednisone and bortezomib (MPV), melpha-
lan, prednisone and thalidomide (MPT) or melphalan and
prednisone (MP).1 Novel agent-based therapies included
immunomodulatory drugs and proteasome inhibitor treat-
ment according to the approved indications and in line
with treatment at other international centers (Table 2). In
order to revise the MCI, the data set was randomly split
into 2/3 and 1/3 of patients, using a training (n=552) and
validation set (n=249). The training set was used to devel-
op the R-MCI and the validation set to validate our results.
Both groups were comparable with respect to relevant
patient-specific and MM-specific data, laboratory parame-
ters and therapy. The data of the entire patient cohort, and
of both the training and validation sets are displayed in
Table 2. Approximately one-half (43%) of the patients
received standard treatment without stem cell transplanta-
tion (SCT), the other percentage of patients includes those
who underwent SCT (Table 2). Patient characteristics
according to treatment are displayed in the Online
Supplementary Table S2. Treatment was not modified
according to the comorbidity scores in line with prior
studies.7-10,12,35,39,40
Frequency of specific comorbidities
Frequent comorbidities (>30%) of all grades were KPS
impairment (94%), renal impairment (68%), frailty (62%),
cardiac impairment (45%), disability (43%) and lung
impairment (32%). More severely graded comorbidities
were again KPS impairment, frailty, disability, renal
impairment, lung impairment, cardiac impairment and
infections. Other comorbid conditions, such as liver and
gastrointestinal impairment and thrombosis occurred to a
lesser extent and severity (Figure 1).
Multivariate analysis for OS, weighting and risk 
stratification via MCI
The multivariate Cox proportional hazards model based
on backward selection revealed five highly significant risks
as relevant for OS (Table 3). Score weights for comorbidities
(Table 3) were determined based on regression coefficients
of the prognostic factors, i.e., log hazard ratios. In a separate
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Table 3. Multivariate Cox proportional hazards model of the training set analysis (n=552) based on backward selection for overall survival (OS),
and the value of inclusion of cytogenetics (n=353). 
Multivariate Cox proportional hazards model of the training set analysis (n=552)
Definition n=552 (%) HR P-value log(HR) Score weight
(2.5-97.5%)
1. Renal disease (eGFRMDRD)a ≥90 184 (33) 1 (-) 0 0
60-89 193 (35) 1.25 (0.92-1.68) <0.0001 0.22 0
<60 175 (32) 1.96 (1.43-2.68) 0.67 1
2. Lung disease No/mild 470 (85) 1 (-) 0.0005 0 0
Moderate/severe 82 (15) 1.65 (1.24-2.18) 0.50 1
3. KPS 100% 35 (6) 1 (-) 0.0036 0 0
80-90% 207 (38) 2.17 (1.04-4.52) 0.77 2
≤70% 310 (56) 2.96 (1.43-6.12) 1.08 3
4. Age (years) <60 226 (41) 1 (-) <0.0001 0 0
60-69 185 (33) 1.43 (1.06-1.92) 0.36 1
≥70 141 (26) 2.08 (1.50-2.89) 0.73 2
5. Frailty No/mild 323 (59) 1 (-) <0.0001 0 0
Moderate 140 (25) 1.54 (1.17-2.04) 0.43 1
Severe 89 (16) 2.02 (1.45-2.82) 0.70 1
± Cytogenetics Favorable 0
Unfavorable 1
Unavailable 0
Maximum points 9
Univariate and bivariate Cox model with and without inclusion of cytogenetics (n=353)
log(HR) HR P-value
(2.5-97.5%)
Univariate Cox model Preliminary score 0.10 1.11 <0.0001
with preliminary score (1.08-1.14)
Multivariable Cox model Preliminary score 0.10 1.11 <0.0001
with inclusion of cytogenetics (1.08-1.13)
Cytogenetics unfavorable 0.44 1.56 0.006
(1.13-2.15)
aeGFR calculated as MDRD 186 × (serum creatinine level [mg/dl]) -1.154 × (age [y]) -0.203 × (0.742 if female, 1.21 if black person), log hazard ratios: parameter estimates.
We assigned a score weight of 0, if the log hazard ratio was below 0.3, a score weight of 1, if the log hazard ratio was between 0.31 and 0.7, a score weight of 2, if the log hazard
ratio was between 0.71 and 1.07, and a score weight of 3, if the log hazard ratio was 1.08 or higher, leading to a maximum of 9 points. This rule very closely approximates the
weights as previously described.35 n: number; HR: hazard ratio; KPS: Karnofsky Performance Status; eGFRMDRD: estimated glomerular filtration rate by MDRD (Modification of Diet
in Renal Disease).
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Table 4. Univariate Cox proportional hazards model for overall survival (OS) - comparison of the R-MCI with other comorbidity scores: I-MCI, CCI,
HCT-CI and KFI.
Score low- vs. moderate- vs. high-riska n (%) HR (2.5-97.5%) P-value
Training analysis (n=552)
R-MCI fit (n=176)
intermediate-fit (n=302) 2.87 (2.14-3.85) <0.0001
frail (n=74) 9.57 (6.52-14.03)
I-MCI fit (n=187)
intermediate-fit (n=225) 2.47 (1.82-3.37) <0.0001
frail (n=140) 4.45 (3.20-6.17)
CCI fit (n=198)
intermediate-fit (n=181) 2.05 (1.51-2.79) <0.0001
frail (n=173) 3.56 (2.65-4.80)
HCT-CI fit (n=155)
intermediate-fit (n=220) 2.29 (1.67-3.15) <0.0001
frail (n=177) 2.84 (2.05-3.92)
KFI fit (n=241)
intermediate-fit (n=118) 2.16 (1.57-2.98) <0.0001
frail (n=193) 3.53 (2.67-4.67)
Validation analysis (n=249)
R-MCI fit (n=71)
intermediate-fit (n=144) 5.26 (2.41-11.49) <0.0001
frail (n=34) 28.35 (12.23-65.69)
I-MCI fit (n=84)
intermediate-fit (n=104) 4.30 (2.11-8.73) <0.0001
frail (n=61) 9.47 (4.61-19.44)
CCI fit (n=120)
intermediate-fit (n=70) 2.37 (1.43-3.93) <0.0001
frail (n=59) 6.40 (3.94-10.41)
HCT-CI fit (n=78)
intermediate-fit (n=93) 1.80 (1.01-3.21) <0.0001
frail (n=78) 5.06 (2.95-8.67)
KFI fit (n=125)
intermediate-fit (n=48) 1.73 (0.98-3.04) <0.0001
frail (n=76) 4.80 (3.00-7.67)
aScoring groups (fit, intermediate-fit, frail) based on the 25% and 75% quartiles of the scores evaluated from the training set. R-MCI: revised Myeloma Comorbidity Index; I-MCI:
initial Myeloma Comorbidity Index; CCI: Charlson Comorbidity Index; HCT-CI: Hematopoietic cell transplantation-specific Comorbidity Index; KFI: Kaplan-Feinstein Index; HR:
hazard ratio; n: number.
Figure 1. Frequency of entire
(blue columns) and moderate-
severe (yellow columns) organ
impairment. Frequency of rele-
vant comorbidities and impair-
ment of general condition in all
MM patients. Proportion of
patients with any degree of impair-
ment/grade of severity (blue bars)
vs. proportion of patients with
moderate to severe
impairment/grade of severity (red
bars). For cardiac function, hepat-
ic function, GI disease, infection,
thrombosis and renal function the
CTCAE grading system was used,
with CTCAE 1-4 (blue bars) vs.
CTCAE ≥2 (red bars). KPS and
lung function was graded as
described.8–10,22,23,46 Frailty was
graded according to the definition
of Rodriguez-Mañas L et al.32 and
Fried LP et al.48 Disability was
graded as described.32,33 Table 1
shows the definition and grading
of all assessed comorbidities. GI:
gastrointestinal; KPS: Karnofsky
Performance Status; pts: patients.
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Figure 2. OS (A-D) and PFS (E-H) using the R-MCI (left) and I-MCI (right) in training and validation analyses. Overall survival (OS: A-D) and progression-free survival
(PFS: E-H) curves using the revised MCI (R-MCI) and initial MCI (I-MCI) in the training and validation sets. Fit patients, with the use of the R-MCI, were defined with
0-3, intermediate with 4-6 and frail patients with 7-9 R-MCI points; with the use of the I-MCI with 0, 1 and 2-3 points, respectively. The survival curves of the R-MCI
were stratified based on 25% and 75% quantiles leading to a stratification of fit patients with ≤3 R-MCI points, intermediate-fit patients with 4-6 R-MCI points and
frail patients with >6 R-MCI points. The numbers of patients at risk in the respective groups are given below each Kaplan-Meier plot. PFS with the use of the R-MCI
generated better group distinction both in the training set (E) and validation set (G) than with the use of the I-MCI (F and H). In line, OS was better distinguishable
in 3 risk groups via the R-MCI in the training set (A) and validation set (C) vs. with the use of the I-MCI (B and D). R-MCI: revised Myeloma Comorbidity Index; I-MCI:
initial Myeloma Comorbidity Index.
A
C
E
G H
F
D
B
model, cytogenetics proved to supplement both additional
and independent information to these risks (Table 3): pre-
diction errors based on the Brier score36 compared the R-
MCI, with and without cytogenetics, and showed the
smallest prediction errors with the R-MCI, with the inclu-
sion of cytogenetics therein (Online Supplementary Figure
S1). The weight for cytogenetics was based on the regres-
sion coefficient from the multivariable Cox model, includ-
ing both the preliminary score and cytogenetics (Online
Supplementary Table S3). A prognostic model was generated
by combining and weighting the risks as displayed in the
Online Supplementary Table S3, showing only marginal
changes compared to the results of the final model used for
determining score weights (Table 3). The R-MCI allowed for
Comprehensive appraisal of a weighted myeloma comorbidity index
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Figure 3. OS with the use of the R-MCI with different treatment intensity and age groups. OS with the use of the R-MCI in different treatment (A-D) and age cohorts
(E,F), demonstrated excellent risk allocations of fit, intermediate and unfit patients with vs. without stem cell transplantation (A,B), with vs. without novel agent treat-
ment (C,D) and <65 vs. >65 year old patients (E,F). Tx: transplantation; NA: novel agents; w: with; w/o: without.
A B
C D
E F
the definition of largely different risk groups: in both training
and validation analyses, it distinguished patients with clearly
different OS and PFS (Figure 2A-H): patients with a R-MCI
of ≤3 were defined as fit (247 patients [30.8%]), those with
a R-MCI of 4-6 as intermediate-fit (446 patients [55.7%])
and those with a R-MCI >6 as frail (108 patients [13.5%]).
The median OS in these defined groups was 10.1, 4.4 and
1.2 years, respectively, in the training set (Figure 2A), and
in the validation set (Figure 2C) not reached (n.r.), 5.9 and
0.8 years, respectively. The median PFS in these groups
was 4.1, 1.9 and 0.9 years, respectively, in the training set
(Figure 2E), and 5.0, 2.3 and 0.8 years in the validation set,
respectively (Figure 2G). From Figure 2, it can also be per-
ceived that in the entire cohort, 13.5% were frail, if
assessed via the R-MCI, whereas if assessed with the I-
MCI, 25.1% of the cohort were determined frail.
Intermediate-fit patients were fairly similar with 56%
assessed intermediate-fit via the R-MCI vs. 41.1% via the I-
MCI. Because the percentages of frail patients are distinc-
tive, this highlights the relevance of performing a compre-
hensive comorbidity, frailty and disability evaluation also
in 'intermediate-old' patients, and that different types of
evaluations (e.g., scores: Table 4), result in diverse percent-
ages of frail patients, namely of 13.5% with the R-MCI,
25.1% with the I-MCI, 29% with the CCI, 32% with the
HCT-CI and 33.6% with the KFI, the latter four most likely
overestimating frailty in MM, which illustrates the value of
a prospectively validated MCI, also in intermediate-old
MM patients.
MCI analysis in different treatment and age groups
To also determine whether the R-MCI remained a signif-
icant risk tool in different treatment and age groups, we
assessed the risk group allocation of fit (R-MCI ≤3), inter-
mediate-fit (R-MCI 4-6) and frail patients (R-MCI >6), with
vs. without SCT (Figure 3A,B), with and without novel
agents (NAs) (Figure 3C,D) and in younger (<65 years) vs.
older patients (≥65 years; Figure 3E,F). In all subgroups, the
value of the R-MCI was confirmed (P<0.0001). Of note, the
R-MCI was a highly valuable risk tool for younger and older
MM patients, demonstrating again that age alone is not suf-
ficient to define fitness and therapy allocation (Figure 3E,F).
Although subgroups of patients were limited, and these
were non-randomized treatment comparisons, it was of
interest that fit patients fared favorably, even without SCT
(Figure 3B [n=72]), without NAs (Figure 3D [n=108]) or ≥65
years (Figure 3F [n=25]; all alive), whereas intermediate-fit
and frail patients in these subgroups performed less favor-
ably as compared to those with SCT (Figure 3A), with NAs
(Figure 3C) or younger patients (Figure 3E). Figures 3E and
3F illustrate that patients <65 years were fit, intermediate-
fit and frail in 48%, 50% and 2%, respectively, whereas in
the >65 year old patient group, 7%, 63% and 29% were fit,
intermediate-fit and frail, respectively. This showed that in
the younger age group, there were also frail patients, albeit
rarely, and that in the older cohort, fit patients were present,
with 2% and 7%, respectively. Moreover, this demon-
strates that frail patients increase with age, whereas inter-
mediate-fit patients remained a very prominent group with
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Figure 4. Scoring factors and maximum points of the R-MCI as compared to the IMWG frailty index, CCI, HCT-CI, KFI and R-ISS. Single factors of respective inter-
nationally used comorbidity scores, namely the IMWG frailty index, HCT-CI, KFI and R-ISS and R-MCI are displayed with their respective comorbidities therein. The
number of risk factors and maximum score that can be achieved is also depicted. Moreover, respective overlapping risk factors with the R-MCI are shown. Impaired
general condition is differently assessed with various scores, e.g., with the R-MCI via Karnofsky Performance Status (KPS) and frailty; with the IMWG frailty index via
ADL and IADL and with the KFI via assessment of any locomotor impairment. IMWG: International Myeloma Working Group; CCI: Charlson Comorbidity Index; (I)ADL:
(Instrumental) Activity of Daily Living; AIDS: Acquired Immune Deficiency Syndrome. HCT-CI: Hematopoietic cell transplantation-specific Comorbidity Index; R-MCI:
revised Myeloma Comorbidity Index; KFI: Kaplan-Feinstein Index; ISS: International Staging System; R-ISS: revised ISS; LDH: lactate dehydrogenase.
50% and 63% in both cohorts, respectively. Treatment was
not modified according to the comorbidity scores, there-
fore, although very infrequently, frail patients (n=6; Figure
3A) as assessed via the R-MCI received transplants; even
more impressively, 72 patients, notwithstanding being
scored as fit via the R-MCI (Figure 3B), did not receive trans-
plantation, suggesting more underutilization or undertreat-
ment than overtreatment in a very rare subset. An even
more detailed comparison of treatment subgroups of
patients receiving more vs. less intensive treatment is
depicted in the Online Supplementary Table S2, which shows
comparable disease characteristics, but, as expected, more
intensive treatment in younger patients.
Comparison of the R-MCI with other comorbidity scores
All patients were divided into three groups of fit, interme-
diate-fit and frail patients based on the 25% and 75% quar-
tiles of the respective scores: the R-MCI, I-MCI, CCI, HCT-
CI and KFI (Table 4). Differences and overlapping similarities
are depicted in Figure 4. The univariate Cox proportional
hazards model revealed that all scores allocated patients into
3 risk groups of fit, intermediate-fit and frail patients, with
increasing HR. All scores reached statistical significance in
terms of OS. Direct comparison of these comorbidity scores
showed that the R-MCI generated the highest HRs in the
training set, increasing to 2.87 and 9.57 for intermediate-fit
and frail patients, respectively. Consistent with these results,
the validation analysis confirmed the highest HRs of 5.26 for
intermediate-fit and 28.35 for frail patients with the use of
the R-MCI, which achieved much higher HRs than those
generated through the use of the I-MCI, CCI, HCT-CI and
KFI. The superiority of both the R- and I-MCI with the high-
est HRs was confirmed in the validation analysis (Table 4)
and via prediction error curves and Brier scores: comparison
of the reference, the R-MCI, I-MCI, KFI, CCI and HCT-CI
demonstrated that the R-MCI generated the most favorable
prediction curves (Online Supplementary Figure S2).
For the exact comparison, both the  I- and R-MCI were
also assessed side by side, both for OS and PFS (Figure 2A-
H). Survival curves of the I-MCI groups with 0, 1 and ≥2 risk
factors, generated clear group allocations of fit, intermedi-
ate-fit and frail patients in both training and validation
analyses, for OS (Figure 2B and 2D) and PFS (Figure 2F and
2H), albeit subgroup allocation via R-MCI was improved
(Figure 2A and 2C, 2E and 2G).
Differences in organ function and comorbidity with 
favorable vs. unfavorable cytogenetics
To determine whether unfavorable cytogenetics were
also associated with organ dysfunction, increased comor-
bidity scores and unfavorable MM-associated characteris-
tics, patients were separated into those with favorable,
unfavorable and unavailable cytogenetics, the latter either
due to patient preference, age, their location in external cen-
ters or other reasons.11,19 Organ impairment differed in
patients with unfavorable or missing vs. favorable cytoge-
netics: the former exhibiting higher frequencies of KPS
impairment, renal impairment, cardiac impairment and
hepatic impairment. Moreover, these patients had more
comorbidities, such as pain, infections and limited physical
conditions with disability and frailty. In line with this, the
R-MCI and KFI increased in patients with unfavorable or
unavailable cytogenetics (Online Supplementary Table S4A).
TheOnline Supplementary Table S4B summarizes the respec-
tive MM patient characteristics: while the median age was
equal in patients with favorable and unfavorable cytogenet-
ics, it was, as expected, more advanced in those with
unavailable cytogenetics, suggesting that cytogenetic analy-
ses were less consistently performed in older patients.
Gender and MM subtype distributions appeared compara-
ble, whereas median β2-MG levels were higher in patients
with unfavorable and unavailable cytogenetics, and BM
infiltration was increased in patients with unfavorable cyto-
genetics. In terms of therapy allocation, the differences
between unfavorable and favorable cytogenetic groups
were less obvious, whereas those with unavailable cytoge-
netics had received less intensive treatment.
Discussion
The results of the present study confirm the prognostic
value of the R-MCI on a large independent patient cohort.22
In order to weight our prior MCI,8-10 13 risk factors were
thoroughly reassessed, including organ function and MM-
specific risks (Table 1). The R-MCI was also compared to
non-MM-specific comorbidity scores, namely CCI, HCT-
CI and KFI. Since we have already compared the MCI and
IMWG frailty score,22 it was not the focus of this analysis,
which was instead to define a weighted validated MM-spe-
cific risk score in a large myeloma cohort. Frequent comor-
bidities in MM proved to be frailty, disability, heart impair-
ment, renal impairment, lung impairment and KPS impair-
ment in agreement with prior studies.3,12,38 Of interest, mul-
tivariate risks (renal impairment, lung impairment, KPS
impairment, age, and frailty) matched with frequent comor-
bidities. Other previously suspected risk factors, such as
liver or gastrointestinal dysfunction,4,5,15 did not reach signif-
icance and proved not to be MM-specific risks. These less
relevant comorbidities were generated from retrospective
studies which were based on multicenter data entries and
had assessed therapy-induced adverse events rather than
baseline comorbidities. Therefore, they may bear the
restriction of validity and information loss. Furthermore,
the frequency of comorbidities in some retrospective stud-
ies was notably low,5,12 which was possibly related to
incomplete multicenter data entries and solely clinical trial
patient inclusion.12
Aside from organ impairment, cytogenetic aberrations
corroborate with impaired OS in MM patients. Our analy-
sis confirmed that cytogenetics provide independent addi-
tional information,17-20,41 and that patients with unfavorable
cytogenetics had higher disease stages, adverse laboratory
values and reduced organ and physical function. Although
cytogenetics proved to be a relevant risk factor, our analysis
also demonstrated that other factors, such as physical and
organ conditions, are equally important. Moreover, the
development of the R-MCI showed that the multivariate
risks (renal function, lung function, KPS, age, and frailty)
defined patients as fit, intermediate-fit and frail, which
could be improved with the inclusion of cytogenetics, but
was also readily usable if this information was unavailable
(Table 3). Weighting of our R-MCI verified that this 9-point
score was able to define 3 patient groups with clearly differ-
ent median PFS and OS. Comparison of the R-MCI with
others (CCI, HCT-CI, KFI) showed that they all divide
patients into risk groups with substantially different OS,
however, Brier scores determined the smallest prediction
errors with the R-MCI. One reason for the comparability of
the R-MCI with other risk scores is that they all include risk
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factors that have some relevance in MM, namely renal func-
tion, lung function and in some physical condition (Figure
4). Compared to our non-weighted I-MCI,8-10 the R-MCI led
to an improvement in group distinction, which highlights
the relevance to further improve a MM-specific risk score as
performed here.
Although the HCT-CI and CCI have been tested and
proven their usefulness,12,35,42 studies in MM have suggest-
ed that both may not have as much impact in MM as the
I-/R-MCI.1,8-10,22,37 This led to some modification of prior
comorbidity scores, albeit in diseases other than MM,40,43-45
and verified that adapted scores (such as the International
Prognostic Index (IPI) for diffuse large B-cell lymphoma,
Mantle Cell Lymphoma International Prognostic Index
(MIPI) for mantel cell lymphoma and Follicular
Lymphoma International Prognostic Index (FLIPI) for fol-
licular lymphoma) are valuable. Moreover, the CCI with
19 different factors, HCT-CI with 17 and KFI with 12
diverse factors are much more complex and time-consum-
ing to assess, whereas the R-MCI involves 5 comorbid
conditions only, uses information which is routinely col-
lected and requires minimal interpretation (Figure 4 and
Online Supplementary Table S1).
The strengths of our R-MCI lie in its inclusion of few
comorbid conditions, that it is readily obtainable from the
collection of the medical history and was obtained from the
analysis of a large sample size. Furthermore, it is valuable
both in younger and older patients. Other notable assets
were that the R-MCI was tested and validated in the same
cohort, randomly splitting the data into a training and vali-
dation set. Additional advantages of the R-MCI are that: 1)
it allows for a more accurate assessment of physical condi-
tions than best clinical judgment, age or KPS alone, 2) it pre-
cisely divides patients into fit, intermediate-fit and frail
patients with definite PFS and OS risk groups, 3) current
and relevant biological risks, namely cytogenetics can, but
don't have to be included, and 4) it is very concise.
Moreover, compared to other international comorbidity
scores (the retrospectively assessed IMWG frailty score,
CCI, HCT-CI and KFI),8-10,22 the R-MCI was particularly
effective in identifying patients at risk.22,25
A limitation of the present study was that the R-MCI was
generated from a large, independent data set, but was
acquired in a single center. Nevertheless, we have compared
our patients to those of other tertiary centers,22,46 demonstrat-
ing that our patients were representative, which is currently
being assessed and affirmed in subsequent analyses and in
prospective multicenter studies. Moreover, the cohort repre-
sented intermediate-old patients, which is typical for com-
prehensive cancer centers (CCCs).7-11,19,22-24,46 Because of the
accumulation of challenging cases in these CCCs, patients
therein show typical comorbidities despite being
"younger".11 Since age is associated with increased comor-
bidity, our results will be even more pertinent for older
patients.8,10,11,22,25 Another criticism might be that different
antimyeloma treatments were applied, nevertheless, in sub-
groups and prior analyses of our group,8,10,22 we demonstrat-
ed that the R-MCI was equally relevant to distinguish highly
significant risk groups (Figure 2 and Figure 3). Nevertheless,
the heterogeneity of therapies may in part describe some
differences in terms of PFS and OS, although it is notewor-
thy that our Kaplan-Meier curves of frail patients with trans-
plants (Figure 3A), with novel agent treatment (Figure 3C)
and in patients <65 years (Figure 3E) distinctly demonstrated
that, despite intensive treatment and younger age, comor-
bidities and frailty induced a poor outcome.
In conclusion, although the retrospectively assessed
IMWG frailty score is considered the "reference", we
demonstrate the validity of this straightforward R-MCI as a
valid prognostic instrument in a large cohort treated accord-
ing to current standards. Based on existing recommenda-
tions, the R-MCI can be applied in routine clinical care, mul-
ticentre analyses and future clinical trials. It may further be
used in research to compare risk profiles of MM cohorts, to
adjust for imbalanced risk profiles and to provide a basis to
establish new clinical or biologic prognostic factors.
Moreover, the R-MCI might be considered as an integral
part in the development of individualized risk-adapted
treatment strategies to further improve outcome in MM.
This includes the correct use of resources, higher inclusion
rates of older patients in clinical studies and the avoidance
of an undersupply of older but fit patients. In the future, the
R-MCI could help to support treatment decisions, aid in
improving tolerability and avoiding toxicity. Since any
prospective comorbidity, frailty and disability evaluation in
MM can be time-consuming, we have implemented the R-
MCI within a web-based technology application which
allows one to perform the MCI expeditiously
(www.myelomacomorbidityindex.org).34 With the retro-
spective "reference IMWG frailty score”,12 ours is an active
website that allows one to calculate a concise MM-specific
comorbidity index which can be tested side by side22,25,46 by
IMWG and EMN experts.
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